慢性乙、丙型肝炎患者肝癌 (HCC)发病率显著增高已成为发达国家令人关注的问题 ,虽然早期诊断提高了生存率 ,但却很难治愈且多在局部治疗或肝移植后复发。肝癌根治术使患者 5年无复发生存率达 2 5 % ,复发后存活时间仅 7～ 2 8个月。术中通过分子生物学技术发现 88%患者肝内有 The significant increase in the incidence of liver cancer (HCC) in patients with chronic hepatitis B and C has become a concern in developed countries. Although early diagnosis improves survival, it is difficult to cure and relapses after topical treatment or liver transplantation. The radical resection of hepatocellular carcinoma results in a 5-year recurrence-free survival rate of 25%, and the recurrence survival time is only 7 to 28 months. Intraoperative detection of 88% of patients in the liver by molecular biology techniques